The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I, single-institution open-label, dose-escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies.
S. R. Ahmed
No relevant relationships to disclose
D. Cosgrove
No relevant relationships to disclose
D. Ball
No relevant relationships to disclose
R. C. Donehower
No relevant relationships to disclose
B. Nelkin
No relevant relationships to disclose
E. Petito
No relevant relationships to disclose
M. Downs
No relevant relationships to disclose
H. X. Chen
No relevant relationships to disclose
A. Doyle
No relevant relationships to disclose
A. Scardina
No relevant relationships to disclose
M. A. Carducci
No relevant relationships to disclose
N. S. Azad
No relevant relationships to disclose